Insulin Resistance and Aging: The Metabolic Root of Disease

If you had to identify a single metabolic dysfunction that underlies the most common age-related diseases, insulin resistance would be the leading candidate. It is a root cause, or at minimum a major contributor, to type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, certain cancers, and increasingly, Alzheimer's disease (now sometimes called "type 3 diabetes" in the research literature).

The insidious part: insulin resistance develops silently over years or decades, causing cellular and vascular damage long before any standard lab test flags a problem. By the time fasting glucose is elevated, significant metabolic dysfunction has typically been present for years.

Understanding insulin resistance, what it is, how it develops, how to detect it early, and what to do about it, may be one of the most important things you can do for your long-term health.

Insulin is a hormone produced by the pancreatic beta cells in response to rising blood glucose. Its primary job is to signal cells, particularly muscle, liver, and fat cells, to take up glucose from the bloodstream. In a healthy metabolic state, a small amount of insulin produces a robust cellular response.

Insulin resistance occurs when cells become less responsive to insulin's signal. The pancreas compensates by producing more insulin to achieve the same effect. For a while, this compensation works. Blood glucose stays normal, but at the cost of chronically elevated insulin levels (hyperinsulinemia).

Over time, the pancreas cannot keep up. Blood glucose begins to rise, first after meals (postprandial hyperglycemia), then in the fasting state. Prediabetes is diagnosed when fasting glucose reaches 100-125 mg/dL or HbA1c reaches 5.7-6.4%. Type 2 diabetes is diagnosed above those thresholds.

But the damage from insulin resistance begins long before the prediabetes threshold, during the years of compensatory hyperinsulinemia when standard glucose tests appear normal.

Chronically elevated insulin promotes several pro-atherogenic processes: increased sodium retention (raising blood pressure), stimulation of smooth muscle cell proliferation in arterial walls, increased triglyceride production, decreased HDL cholesterol, and promotion of a pro-inflammatory state.

Insulin resistance is now recognized as a major independent risk factor for cardiovascular disease, separate from its role in causing diabetes. The INTERHEART study, which examined risk factors for heart attack across 52 countries, found that metabolic syndrome (largely driven by insulin resistance) accounted for approximately 50% of population-attributable risk.

The brain is an insulin-sensitive organ. Insulin resistance in the brain impairs glucose metabolism in neurons, promotes amyloid-beta accumulation, and drives neuroinflammation, all hallmarks of Alzheimer's disease pathology.

A 2005 study by Suzanne de la Monte coined the term "type 3 diabetes" to describe the insulin resistance and impaired insulin signaling found in Alzheimer's brains. Subsequent research has consistently found that type 2 diabetes roughly doubles the risk of Alzheimer's disease, and that insulin resistance, even without diabetes, is associated with accelerated cognitive decline.

Hyperinsulinemia promotes cancer through multiple mechanisms: insulin is a growth factor that activates IGF-1 signaling, promotes cell proliferation, and inhibits apoptosis (programmed cell death). Elevated insulin also drives obesity and inflammation, both of which are independent cancer risk factors.

A 2011 meta-analysis found that type 2 diabetes was associated with significantly increased risk of cancers of the liver, pancreas, endometrium, colon, rectum, breast, and bladder.

Insulin resistance drives oxidative stress and chronic inflammation, two of the primary mechanisms of cellular aging. It also impairs mitochondrial function, reduces autophagy, and promotes the accumulation of advanced glycation end-products (AGEs), damaged proteins and lipids that stiffen tissues and drive inflammation.

Standard fasting glucose and HbA1c tests miss early insulin resistance because they measure glucose, not insulin. By the time glucose is elevated, significant metabolic dysfunction has already occurred.

More sensitive markers include:

Fasting insulin: Should ideally be below 5-8 uIU/mL. Many labs consider up to 25 uIU/mL "normal," but this reflects the population average, not optimal metabolic health.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance): Calculated from fasting glucose and fasting insulin. A score above 1.5-2.0 suggests insulin resistance; above 2.9 is clearly elevated.

Triglyceride-to-HDL ratio: A ratio above 2.0 (in mg/dL units) is a strong proxy for insulin resistance and small, dense LDL particles. This is one of the most underutilized and informative markers in standard lipid panels.

Waist circumference: Visceral fat, the fat stored around abdominal organs, is both a cause and consequence of insulin resistance. Waist circumference above 40 inches in men or 35 inches in women is associated with significantly elevated metabolic risk.

Postprandial glucose: Continuous glucose monitors (CGMs) can reveal glucose spikes after meals that are invisible on fasting tests. Many metabolically healthy-appearing people have significant postprandial dysregulation.

The primary drivers are well-established:

Excess caloric intake and visceral fat accumulation: Visceral fat releases free fatty acids and inflammatory cytokines that directly impair insulin signaling in muscle and liver.

Physical inactivity: Skeletal muscle is the primary site of insulin-stimulated glucose disposal. Inactive muscle becomes insulin resistant. Exercise is one of the most potent insulin sensitizers known.

Ultra-processed food and refined carbohydrates: Rapidly digested carbohydrates cause large glucose spikes that demand large insulin responses, driving the cycle of hyperinsulinemia.

Sleep deprivation: Even one night of poor sleep measurably impairs insulin sensitivity. Chronic sleep deprivation is a significant driver of metabolic dysfunction.

Chronic stress: Cortisol directly antagonizes insulin signaling and promotes visceral fat accumulation.

Aging itself: Insulin sensitivity declines with age independent of other factors, partly due to reduced muscle mass, mitochondrial dysfunction, and increased visceral fat.

Exercise, particularly a combination of resistance training and aerobic exercise, is the most effective intervention for improving insulin sensitivity. Muscle contraction activates GLUT4 transporters independently of insulin, allowing glucose uptake without insulin signaling. Regular exercise also increases muscle mass, which expands the body's glucose disposal capacity.

A 2016 meta-analysis found that combined aerobic and resistance training reduced HbA1c by 0.67% in people with type 2 diabetes, comparable to some medications.

No single dietary pattern has a monopoly on improving insulin sensitivity. The common thread across effective dietary interventions is reducing refined carbohydrates and ultra-processed foods, increasing fiber, and achieving a caloric deficit if visceral fat is present.

Low-carbohydrate diets produce the most rapid improvements in fasting glucose and insulin. Mediterranean-style diets produce more modest but sustained improvements and have the strongest long-term cardiovascular evidence. Time-restricted eating improves insulin sensitivity partly through caloric restriction and partly through circadian alignment.

Optimizing sleep quality and duration (7-9 hours for most adults) is a high-leverage intervention for metabolic health that is often overlooked. A 2010 study found that restricting sleep to 5.5 hours per night for two weeks reduced insulin sensitivity by 25%.

Chronic cortisol elevation directly impairs insulin signaling. Stress management practices, whether meditation, exercise, social connection, or adequate leisure, are not soft additions to a metabolic health strategy. They are mechanistically important.

Insulin resistance is not just a precursor to diabetes. It is a fundamental driver of cardiovascular disease, neurodegeneration, cancer, and accelerated biological aging. It develops silently for years before standard tests detect it, and it is largely preventable and reversible through lifestyle.

Getting a fasting insulin level and calculating your HOMA-IR is one of the most informative things you can do at your next physical. Understanding where you stand metabolically, not just whether your fasting glucose is "normal," is foundational to any serious longevity strategy.

David Goldfarb, DO, FACS served for 26 years as Chief of Otolaryngology-Head & Neck Surgery at Penn Medicine Princeton Medical Center. His book, The Ultimate Anti-Aging Blueprint, covers the full spectrum of evidence-based longevity strategies.